Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion

TheFly reported connected January 8 that Wolfe Research expert Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 terms target. The steadfast described the five-year gross outlook arsenic “attractive” and stated that the banal is “poised for a breakout” aft accretive M&A and up of a catalyst-rich epoch aft integrating MRK’s late-stage pipeline, imaginable statement expansions, and prescriber feedback into its models.

Separately, connected January 9, reports emerged that MRK is successful progressive talks to get Revolution Medicines for astir $30 billion.

Merck & Co., Inc. (NYSE:MRK) is simply a starring oncology institution driven by its blockbuster immunotherapy Keytruda, with a diversified crab portfolio spanning immuno-oncology, targeted therapies, and operation regimens, supported by an expanding objective pipeline and strategical acquisitions to prolong semipermanent growth.

While we admit the imaginable of MRK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.